Key Insights

Highlights

Treatment Research

1 treatments under study, led by Zopapogene Imadenovecdrba

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Research Network

Common Treatments

  • Zopapogene Imadenovecdrba1

Active Sponsors

  • Precigen, Inc1

Related Conditions

  • Papillomavirus Infections1
  • Recurrent Respiratory Papillomatosis Rrp1

Activity Timeline